310 related articles for article (PubMed ID: 26982012)
1. Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
Khanna R; Mosli MH; Feagan BG
Dig Dis; 2016; 34(1-2):153-9. PubMed ID: 26982012
[TBL] [Abstract][Full Text] [Related]
2. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
Poulakos M; Machin JD; Pauly J; Grace Y
J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
4. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano ML
World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
[TBL] [Abstract][Full Text] [Related]
8. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
McLean LP; Cross RK
Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
10. What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?
Card T; Xu J; Liang H; Bhayat F
Inflamm Bowel Dis; 2018 Apr; 24(5):953-959. PubMed ID: 29668955
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
Smith MA; Mohammad RA
Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
Garnock-Jones KP
BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.
Tilg H; Kaser A
Curr Opin Investig Drugs; 2010 Nov; 11(11):1295-304. PubMed ID: 21157649
[TBL] [Abstract][Full Text] [Related]
14. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
Wyant T; Fedyk E; Abhyankar B
J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
Sands BE
Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
[TBL] [Abstract][Full Text] [Related]
16. [Emerging Therapies: What Are Promising in the Near Future?].
Seo GS; Lee SH
Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
[TBL] [Abstract][Full Text] [Related]
17. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
18. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
19. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
[TBL] [Abstract][Full Text] [Related]
20. Anti-integrin therapy for inflammatory bowel disease.
Park SC; Jeen YT
World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]